Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InhaleRx Limited ( (AU:IRX) ) has provided an update.
InhaleRx Limited has commenced manufacturing its lead investigational product, IRX-211, for a Phase 2 clinical trial targeting breakthrough cancer pain, marking a significant operational milestone. The manufacturing is being conducted by Ab Initio Pharma, and this step signifies the company’s transition from development to clinical supply readiness, potentially offering a much-needed solution for patients and strengthening its market position.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical-stage drug development company focused on creating rapid onset inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The company is working on obtaining U.S. FDA approval for its products using efficient regulatory pathways, with a significant economic opportunity anticipated for shareholders.
Average Trading Volume: 317,166
Technical Sentiment Signal: Buy
Current Market Cap: A$7.9M
For an in-depth examination of IRX stock, go to TipRanks’ Overview page.